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During Gram-negative sepsis, lipopolysaccharide (LPS) activates toll-like receptor (TLR) 4 and induces complex responses of
immune system and coagulation. However, the underlying LPS signalling mechanism on coagulation activation remains complex.
To determine the role of the intracellular signalling factors p38 mitogen-activated protein kinase (MAPK), nuclear factor-kappa
B( N F - κB), and c-Jun N-terminal kinase (JNK) in the procoagulant response to LPS, coagulation process of human whole
blood exposed to speciﬁc inhibitors was measured by thrombelastography. Samples were stimulated with LPS (100μg/mL) after
preincubation with BAY117082 (speciﬁc NF-κB inhibitor), SP600125 (speciﬁc JNK inhibitor), SB203580 (speciﬁc p38 MAPK
inhibitor),orvehicle.SB203580stronglyinhibitedLPS-inducedcoagulationactivation,whereasBAY117082andSP600125showed
no signiﬁcant eﬀect. Activation of p38 MAPK, NF-κB, and JNK and respective inhibitory eﬀects were conﬁrmed by Multi-Target
Sandwich ELISA. In conclusion, activation of p38 MAPK is crucial for early LPS-induced activation of coagulation.
1.Introduction
Activation of the coagulation system is an important part
of the systemic inﬂammatory response during infection.
Lipopolysaccharide (LPS), a complex outer membrane gly-
colipid of Gram-negative bacteria, triggers an array of cel-
lular activations through a variety of mechanisms involving
diverse intracellular signalling [1–3]. In patients with Gram-
negative sepsis bacterial LPS induces the expression of tissue
factor (TF) on monocytes and endothelial cells, leading
to disseminated intravascular coagulation [4, 5]. However,
mechanisms involved in LPS-induced coagulation activation
remain complex. Binding of LPS to toll-like receptor (TLR)
activates several intracellular signalling cascades that include
nuclear factor-kappa B (NF-κB), c-Jun N-terminal kinase
(JNK), and p38 mitogen-activated protein kinase (MAPK)
[6, 7]. The roles of NF-κB, JNK, and p38 MAPK in
activation of coagulation in vivo are not completely known.
Therefore the present study was designed to investigate the
eﬀects of BAY117082, SP600125, and SB203580, speciﬁc and
potent inhibitors of NF-κB, JNK, and p38 MAPK, in the
procoagulant response to LPS in healthy subjects measured
by thrombelastography (TEG).
2.MaterialsandMethods
2.1. Blood Sampling and Incubation of Whole Blood Samples.
After receiving written informed consent, venous blood
from eleven healthy volunteers was collected in one-tenth
volume of citrate (3.8%, Becton Dickinson, Heidelberg,
Germany) and immediately used for the experiments.
Blood samples were incubated with 1, 10, or 100μM
BAY117082, SP600125, SB203580, or vehicle for 1h. There-
after, 100μg/mL Escherichia coli LPS (Serotype 0111:B4,
Sigma-Aldrich, Germany) was added for further 15min in
ELISA experiments or further 4h in TEG experiments. All
incubations were performed at 37◦C.2 ISRN Hematology
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Figure 1: Phosphorylation of p38 MAPK, NF-κB, and JNK after LPS stimulation with or without preincubation with speciﬁc inhibitors.
Whole blood was stimulated with LPS (100μg/mL) for 15min. After ﬁxing and washing, protein lysates were prepared and subjected to
ELISA analysis for phosphorylated forms of p38 MAPK, NF-κB, and JNK. Means ± SD of optical densities are expressed as the levels
of activation relative to controls (set to 100%). ∗P<0.05 versus data for control; ∗∗P<0.05 versus data for LPS. BAY=BAY117082,
SB=SB203580, SP=SP600125.
2.2. Determination of Clotting Time and Clot Firmness.
Whole blood clotting time (CT) and maximal clot ﬁrmness
(MCF) were determined as described [8]. In short, citrated
whole blood samples containing LPS and a speciﬁc inhibitor,
as stated in the respective experiments, were recalciﬁed with
calcium chloride and subjected to rotational thrombelastog-
raphy (Roteg 5, Pentapharm, Munich, Germany), a modiﬁ-
cation of the original thrombelastography method [9].
2.3. Inhibition of NF-κB p65, p38 MAPK, and JNK Sig-
nalling Pathways. Following incubation period reaction was
stopped by Lyse/Fix Buﬀer (BD Phosﬂow, BD, San Jode,
USA). After a wash with phosphate-buﬀered saline, protein
lysates were prepared using the lysis buﬀer included in the
PathScan Inﬂammation Multi-Target Sandwich ELISA Kit
(Cell Signaling, Danvers, USA). The lysates were subjected
to ELISA analysis for the phosphorylated forms of NF-κB
p65, p38 MAPK, and JNK in duplicate using the ELISA Kit
according to the manufacturer’s instructions.
2.4. Statistical Analysis. All results are given as mean and
standard deviation. The normality distribution was tested
using Kolmogorov-Smirnov test showing that all variables
were normally distributed. The results were evaluated using
one-way analysis of variance (ANOVA). Statistical signiﬁ-
cance was set at P<0.05. After testing homogeneity of vari-
ancebyLevenetest,theTukeyHSDposthoctestwasselected
for all analyses. All analyses were done using PASWStatistics
18.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Phosphorylation of p38 MAPK, NF-κB, and JNK after
LPS Stimulation with or without Preincubation with Spe-
ciﬁc Inhibitors. Stimulation of blood with 100μg/mL LPS
induced rapid phosphorylation of NF-κB and p38 MAPK
within 15min. NF-κB phosphorylation increased 2-fold
(217±33%) and p38 MAPK phosphorylation increased 1.5-
fold (145 ± 4%) (Figures 1(a) and 1(b)). In contrast, JNK
showed no alteration in phosphorylation after incubationISRN Hematology 3
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Figure 2: Clotting time (CT) in whole blood after LPS stimulation with or without preincubation with speciﬁc inhibitors. (a) Levels of CT
of whole blood under control conditions, in the presence of LPS (100μg/mL) for 4 hours and after pretreatment with 100μM BAY117082
(BAY), 100μM SP600125 (SP), or SB203580 (SB) for 1 hour. Data are presented as mean ± SD. ∗P<0.05 versus data for LPS. (b) Levels of
CT of whole blood under control conditions, in the presence of LPS (100μg/mL) for 4 hours, and after pretreatment with 1μM, 10μM, or
100μM SB203580 (SB) for 1 hour. Data are presented as means ± SD. ∗P<0.05 versus data for LPS.
with LPS (Figure 1(c)). Preincubation with the p38 MAPK
inhibitor SB203580 and NF-κB inhibitor BAY117082 com-
pletely blocked the LPS-activated phosphorylation of p38
MAPKandNF-κB,respectively.TheJNKinhibitorSP600125
diminished JNK phosphorylation almost by half (Figure 1).
The inhibition eﬀect after LPS stimulation of all three
inhibitors showed similar eﬀects:BAY117082 reducedNF-κB
phosphorylation from 217% to 129% (−41%), SB203580
reduced p38 MAPK phosphorylation from 145% to 105%
(−28%), and SP600125 reduced JNK phosphorylation from
110% to 61% (−44%), respectively.
3.2. Clotting Time (CT) in Whole Blood after LPS Stimula-
tion with or without Preincubation with Speciﬁc Inhibitors.
During incubation of whole blood with 100μg/mL LPS
over a period of 4 hours, we observed a reduction of CT
from 579 ± 76sec to 145 ± 25sec (Figure 2). Preincubation
with the p38 MAPK inhibitor SB203580 inhibited LPS-
induced coagulation (Figure 2(b)). Preincubation with 1μM
SB203580 increased CT from 145 ± 25 to 330 ± 114sec,
10μM SB203580 to 329 ± 69sec, and 100μM SB203580 to
512 ±12sec, respectively.
In contrast to the marked eﬀects of SB203580, admin-
istration of BAY117082, a selective NF-κB inhibitor, and
SP600125, a selective JNK inhibitor, showed no signiﬁcant
eﬀect on CT (Figure 2(a)). Preincubation with 100μM
BAY117082 and 100μM SP600125 increased CT from 145 ±
25sec to 191 ± 44sec and from 145 ± 25sec to 218 ± 26sec,
respectively.
4. Discussion
We recently demonstrated that inhibition of LPS-induced
p38 MAPK activation in neonatal and adult blood was
associated with a strong reduction in release of cytokines,
whereas pharmacological inhibition of NF-κB showed no
eﬀect [10]. In the present study we investigated the role of
p38 MAPK, NF-κB, and JNK for activation of hemostasis
measured by TEG.
For the determination of coagulation in whole blood
samples, we used TEG as reported previously [8]. Although
fast and simple, TEG is able to analyse and dissect single
steps of the dynamic process of blood coagulation diﬀeren-
tially, beginning from activation of clotting factors through
ﬁbrin formation, platelet aggregation, and, ﬁnally, clot lysis
[11]. The sensitivity of this method is high, as shown by
concentration response curve for TF, because exogenously
applied TF shortened clotting time at concentrations as low
as 100fM. This concentration is 60 times smaller than the TF
concentration evoked by LPS in the present study [12]. We
used LPS at a concentration of 100μg/mL to stimulate coag-
ulation cascade. This concentration was chosen according to
aconcentrationresponsecurvewhichwasconstructedunder
identical experimental conditions [13]. The 50% eﬀective
concentration (EC50) of the LPS eﬀect in that study was
18μg/mL, and this value corresponds well to the concentra-
tion range of other whole blood studies [14–16]. Therefore
we decided to maximally stimulate coagulation using the
ﬁvefold concentration in the present study. The relevance
of the chosen LPS concentration is underlined by the fact
that the LPS content of erythrocytes from septic patients has
been demonstrated by our group to be 77 ± 26μg/mL [17].
Furthermore, the procoagulant eﬀects of LPS was demon-
stratedtobemediatedbydenovosynthesisofTF,sincecyclo-
heximide and active site-inhibited factor VIIa, respectively,
completely inhibited the LPS-induced shortening of CT
[13].
StimulationofbloodwithLPSinducedrapidphosphory-
lation of p38 MAPK and NF-κB within 15min, whereas JNK
were not altered. Several authors have implicated NF-κBa n d
p38 MAPK to be critical mediators of the release of inﬂam-
matory cytokines and regulate the expression of a variety of
g e n e si n v o l v e di nt h ea c u t e - p h a s er e s p o n s es u c ha sT N F - α,
IL-6, and other inducible enzymes [18, 19]. Preincubation
withthep38MAPKinhibitorSB203580andNF-κBinhibitor
BAY117082 blocked the LPS-activated phosphorylation of
p38 MAPK and NF-κB to control values, respectively. The
JNK inhibitor SP600125 diminished JNK phosphorylation
almost by half. Concerning inhibition eﬀect after LPS
stimulation, SP600125 showed similar properties compared
to SB203580 and BAY117082.4 ISRN Hematology
Incubation with LPS was associated with induction of
coagulation cascade, as reﬂected by strong reduction of CT.
Since tissue factor is essential for activation of the coagu-
lation cascade [20, 21] and p38 MAPK inhibition reduces
LPS-induced tissue factor, the anticoagulatory activity of
SB203580 may be due to suppression of the LPS-induced
tissue factor upregulation [22]. Furthermore, reduced proin-
ﬂammatory response through p38 MAPK inhibition might
haveanadditionalinhibitoryeﬀectonactivationofhemosta-
sis [10, 23–25]. In contrast to the marked eﬀects of SB203580
on CT, the inhibitor did not aﬀect maximal clot ﬁrmness
(MCF) (not depicted), which is dependent on ﬁbrinogen
polymerization, platelet number, and function, conﬁrming
the expected eﬀect of SB203580 on tissue factor inhibition.
Although LPS strongly activates NF-κB, administration
of BAY117082, a selective NF-κB inhibitor, showed no sig-
niﬁcant eﬀect on CT. In line, we recently demonstrated that
inhibitionofNF-κBhadnosigniﬁcanteﬀectonLPS-induced
early cytokine expression in neonatal and adult whole blood
[10].
Furthermore,LPSactivationofcellsofmonocyticlineage
rapidly activates the JNK pathway [26]. Many of the down-
stream targets of the JNK pathway are transcription factors
including c-Jun, ATF-2, and Elk-1 which regulate transcrip-
tion of proinﬂammatory mediators, like TF [27]. However,
in the present study JNK pathway was not activated by LPS,
and selective inhibition of JNK showed no eﬀect on LPS-
induced coagulation. These results are in line with recently
ﬂow cytometric analysis of human monocytes showing no
signiﬁcant changes in phosphorylation of JNK after LPS
stimulation [28]. According to our knowledge all other stud-
ies, which showed LPS-mediated activation of JNK pathway,
were done in (tumor) cell line models and therefore diﬃcult
to compare. We suggest that NF-κB and JNK activation play
a minor role in LPS-mediated early systemic inﬂammatory
response and early activation of coagulation.
In conclusion we purport that p38 MAPK is crucially
involved in early activation of coagulation during LPS stim-
ulation. To conﬁrm procoagulatory properties of p38 MAPK
during inﬂammation further in vivo studies using speciﬁc
inhibitors are necessary [29].
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